Premium
Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus
Author(s) -
Andriessen Peter,
Struis Nicole C.,
Niemarkt Hendrik,
Oetomo Sidarto Bambang,
Tanke Ronald B.,
Van Overmeire Bart
Publication year - 2009
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2009.01224.x
Subject(s) - furosemide , medicine , ductus arteriosus , creatinine , gestational age , renal function , hyponatremia , urine , diuretic , gastroenterology , endocrinology , pregnancy , genetics , biology
Objective: To evaluate the effect of furosemide on renal function and water balance in preterm infants treated with indomethacin (3 × 0.2 mg/kg at 12‐h intervals) for symptomatic patent ductus arteriosus. Patients and Methods: We performed a retrospective multi‐centre double cohort study in preterm infants <32 weeks of gestational age. Thirty‐two infants treated with furosemide (1 mg/kg i.v.) before each indomethacin dose (furosemide group) were matched with 32 infants with indomethacin treatment alone (control‐group). Renal effects (urine output, weight gain, serum creatinine, sodium concentration) were registered. Results: The study groups were comparable for gestational age, birth weight and day of therapy. Pretreatment differences were observed for urine output, weight and serum sodium. However, no differences were noticed in day‐to‐day urine output change or weight gain between the groups. A significant increase in serum creatinine concentration (50% vs. control, 18%; p < 0.05) and a concomitant significant decrease in serum sodium (–9 vs. control, –3 mmoL/L; p < 0.05) in the furosemide group was observed 72–96 h after starting therapy. Conclusion: Furosemide before each indomethacin dose resulted in a significant increase in serum creatinine and hyponatremia, without increasing urine output.